Abcam PLC ADR ABCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABCM is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $231.00
- Day Range
- $231.00–231.00
- 52-Week Range
- $231.00–292.38
- Bid/Ask
- $244.60 / $231.00
- Market Cap
- $67.17 Bil
- Volume/Avg
- 78,655 / 24,036
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,800
- Website
- https://www.abcam.com
Comparables
Valuation
|
Metric
|
ABCM
|
ZURA
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.77 | 2.66 | 2.43 |
Price/Sales | — | — | 28.54 |
Price/Cash Flow | — | — | — |
Price/Earnings
ABCM
ZURA
NYKD
Financial Strength
|
Metric
|
ABCM
|
ZURA
|
NYKD
|
|---|---|---|---|
Quick Ratio | 0.99 | 4.92 | 7.91 |
Current Ratio | 1.35 | 4.97 | 8.04 |
Interest Coverage | 0.93 | — | −235.75 |
Quick Ratio
ABCM
ZURA
NYKD
Profitability
|
Metric
|
ABCM
|
ZURA
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | 6.16% | −71.08% | −19.18% |
Return on Equity (Normalized) | 8.92% | −139.85% | −26.31% |
Return on Invested Capital (Normalized) | 7.46% | −99.89% | −30.96% |
Return on Assets
ABCM
ZURA
NYKD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xwskmhbm | Vkjc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fmjrwnnt | Mttvyz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nrpcggxxz | Jmrjhl | $97.8 Bil | |
MRNA
| Moderna Inc | Mhmrymvr | Zfb | $41.3 Bil | |
ARGX
| argenx SE ADR | Mmtyyxct | Dklt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Myvtdvhx | Ssyl | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mxpckxj | Gtqvbl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jkbzqlmph | Vrxcyr | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pbqysfpyjp | Mbsznyk | $12.5 Bil | |
INCY
| Incyte Corp | Bpkmgph | Xwffxzf | $11.6 Bil |